Skip to main content

Table 2 Archived antiretroviral drug resistance mutations among study participants

From: HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study

Subject no. Major NRTI resistance mutations Major NNRTI resistance mutations Major PI resistance mutations
Non-TAMs TAMs
1 184V 67N, 70R, 219Q 103N ND
2 184V, 74V 67N, 70R, 219Q 181C, 190A ND
3 184V 41L, 210W, 215Y ND ND
4 184V 70R ND ND
5 184V, 74I 41L, 67N, 70R, 215F, 219Q 103N 84V, 90M
6 184V 41L, 67N, 70R, 215Y, 219Q 103N, 181C, 190S 30N, 88D
7 184V 41L, 215Y 103N 54V, 82A
8 184V 41L, 215Y 98Ga 46L
9 184I, 70E ND ND ND
10 ND ND ND ND
  1. Reference: Stanford HIV Drug Resistance Database. Major HIV-1 Drug Resistance Mutations, Updated summary March 9, 2015. http://hivdb.stanford.edu
  2. NRTI nucleoside analogue reverse transcriptase inhibitor, TAMs thymidine analogue mutations, NNRTI nonnucleoside analogue reverse transcriptase inhibitor, PI protease inhibitor, ND none detected
  3. aAlthough not listed as major NNRTI mutation, 98G confers resistance to nevirapine